Maze Therapeutics (MAZE) Current Assets (2024 - 2026)
Maze Therapeutics (MAZE) posted Current Assets of $379.8 million for Q1 2026, up 8.6% sequentially from $349.7 million in Q4 2025, and up 26.72% YoY from $299.7 million in Q1 2025.
Maze Therapeutics (MAZE) Current Assets (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Current Assets for 3 years, with the latest figure at $379.8 million in Q1 2026.
- Quarterly Current Assets rose 26.72% year-over-year to $379.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $379.8 million (up 26.72% YoY) and the FY2025 annual result came in at $349.7 million, up 73.41% from the prior year.
- Current Assets advanced to $379.8 million in Q1 2026 per MAZE's latest filing, from $349.7 million in the prior quarter.
- Over five years, Current Assets peaked at $391.3 million in Q3 2025 and troughed at $201.7 million in Q4 2024.
- A 3-year average of $315.6 million and a median of $324.7 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2025 and 2026: Current Assets surged 73.41% in 2025, then advanced 26.72% in 2026.
- Over 3 years, Current Assets stood at $201.7 million in 2024, then soared by 73.41% to $349.7 million in 2025, then rose by 8.6% to $379.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $379.8 million, $349.7 million, and $391.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 420.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 420.42 Mn |
| Mar 31, 2026 | 379.78 Mn |
| Dec 31, 2025 | 349.72 Mn |
| Sep 30, 2025 | 391.30 Mn |
| Jun 30, 2025 | 271.15 Mn |
| Mar 31, 2025 | 299.71 Mn |
| Dec 31, 2024 | 201.67 Mn |